This Market Spotlight report covers the Osteoarthritis market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
Key Takeaways
- The author estimates that in 2016, there were 301.6 million prevalent cases of osteoarthritis (knee or hip) in adults aged 30 years and older worldwide, and forecaststhat number to increase to 352.2 million prevalent cases by 2025.
- The global prevalence of osteoarthritis is estimated to be 8.2%. Approved drugs in the osteoarthritis space focus on a wide variety of targets. The approved therapies are commonly administered via the oral route, with a few products being available in topical, intraarticular, and transdermal formulations.
- The majority of industry-sponsored drugs in active clinical development for osteoarthritis are in Phase II. Therapies in mid- and late-stage development for osteoarthritis focus on a wide variety of targets. These drugs are administered via various routes, including oral, transdermal, subcutaneous, intraarticular, intravenous, and subcutaneous administration.
- High impact upcoming events for drugs in the osteoarthritis space comprise topline Phase II and Phase III trial results, and an expected regulatory meeting with the FDA.
- There have been 41 licensing and asset acquisition deals involving osteoarthritis drugs during 2013–18. The largest deal was the $454m license agreement between Novartis and XOMA in August 2017, pursuant to which Novartis was granted a worldwide, exclusive, royalty-bearing license to XOMA’s gevokizumab program.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for osteoarthritis have been in the early and mid-phases of development, with 57% of trials in Phase I–II, and 43% in Phase III–IV.
- The US has a substantial lead in the number of osteoarthritis clinical trials globally. The UK leads the major EU markets, while South Korea has the top spot in Asia.
- Pfizer has the highest number of completed clinical trials for osteoarthritis with 106 trials, and also leads industry sponsors with the highest number of total clinical trials for osteoarthritis, followed by Merck & Co and Sanofi
Table of Contents
OVERVIEWKEY TAKEAWAYSDISEASE BACKGROUNDEPIDEMIOLOGYPIPELINE DRUGSKEY UPCOMING EVENTSPARENT PATENTSREVENUE OPPORTUNITYAPPENDIX
TREATMENT
MARKETED DRUGS
KEY REGULATORY EVENTS
LICENSING AND ASSET ACQUISITION DEALS
CLINICAL TRIAL LANDSCAPE
BIBLIOGRAPHY
LIST OF FIGURES
LIST OF TABLES
Companies Mentioned
- Novartis
- XOMA
- Sanofi
- Merck & Co
- Mitsubishi
- Flexion
- Limited Japan
